Answers are grounded in this paper and cite their sources.
The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.
No takes yet. Share an insight, caveat, or question.
Tie et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: